COVID-19: ICT, Lasa succeed in Favipiravir drug synthesis

COVID-19: ICT, Lasa succeed in Favipiravir drug synthesis

MUMBAI, June 18, 2020:  Veterinary API Major Lasa Supergenerics and Institute of Chemical Technology have achieved success in Favipiravir drug synthesis.

The two entities had come together in the month of March 2020 in effort to bring the antiviral to the market as a promising therapy to fight the ongoing Covid-19 pandemic.

Prof. Vikas N Telvekar, ICT, Mumbai, said “we are happy to share with you that the Favipiravir molecule has been successfully synthesized in the ICT laboratory on a lab scale and further pilot plan scale up is required.”

Dr Omkar HerlekarChairman– Lasa Supergenerics Limited, said the plans are to manufacture close to 10,000 doses to begin with. “Our move into human steroid API is in line with the organisations inherent strengths and objectives to diversify,” he said.

Lasa, in its Q4 results, reported a healthy increase in its PAT to Rs 3.63 cr for FY20, as compared to a loss of Rs 12.04 cr in the corresponding period last fiscal

Institute of Chemical Technology (ICT) Formerly the University Department of Chemical Technology (UDCT) is a Public deemed University specialized in Chemical Technology located in Mumbai, India. It is focused in training and research in various branches of chemical engineering, chemical technology and pharmacy.

Favipiravir is an antiviral drug and is a promising antidote for the treatment of Coronavirus disease (COVID-19). With its effectiveness against many RNA viruses, it is a guanine analogue approved for influenza treatment. It can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus, and a recent study reported its activity against 2019-nCoV.

Incorporated in 2011, Lasa is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea etc.

Recent News